TY - JOUR
T1 - The challenge of CDG diagnosis
AU - Francisco, R.
AU - Marques-da-Silva, D.
AU - Brasil, S.
AU - Pascoal, C.
AU - dos Reis Ferreira, V.
AU - Morava, E.
AU - Jaeken, J.
N1 - Funding Information:
This work was supported by the CDG Professionals and Patient Associations International Network (CDG§ Allies-PPAIN): Pascoal C and Brasil S were awarded the 5th and 6th Liliana Scientific Initiation Scholarship, respectively. Francisco R. was supported by a scholarship (SFRH/BD/124326/2016) from Fundaçâo para a Ciência e Tecnologia (FCT).
Funding Information:
This work was supported by the CDG Professionals and Patient Associations International Network (CDG§ Allies-PPAIN): Pascoal C and Brasil S were awarded the 5th and 6th Liliana Scientific Initiation Scholarship, respectively. Francisco R. was supported by a scholarship ( SFRH/BD/124326/2016 ) from Fundaçâo para a Ciência e Tecnologia (FCT) .
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/1
Y1 - 2019/1
N2 - Congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic diseases that currently includes some 130 different types. CDG diagnosis is a challenge, not only because of this large number but also because of the huge clinical heterogeneity even within a number of CDG. In addition, the classical screening test, serum transferrin isoelectrofocusing, is only positive in about 60% of CDG, and can even become negative in some CDG particularly in PMM2-CDG, the most frequent N-glycosylation defect. In order to facilitate CDG diagnosis, we hereby provide some practical tools: (1) a list of clinical features strongly suggestive of a distinctive CDG; (2) a table of clinical, biochemical and laboratory findings reported in CDG, arranged per organ/system; (3) an overview of the affected organs/systems in each CDG; and (4) a diagnostic decision tree in face of a patient with a suspicion of CDG. Most important is to keep in mind a CDG in any unexplained syndrome, in particular when there is neurological involvement. This mini-review enumerates clinical and biochemical hallmarks of these diseases and the biochemical and genetic testing available, and provides an updated list and information on identified CDG. The main aim is to act as a CDG diagnosis simplified guide for healthcare professionals and, additionally, as an awareness and lobbying tool to help in the effectiveness and promptness of CDG diagnosis.
AB - Congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic diseases that currently includes some 130 different types. CDG diagnosis is a challenge, not only because of this large number but also because of the huge clinical heterogeneity even within a number of CDG. In addition, the classical screening test, serum transferrin isoelectrofocusing, is only positive in about 60% of CDG, and can even become negative in some CDG particularly in PMM2-CDG, the most frequent N-glycosylation defect. In order to facilitate CDG diagnosis, we hereby provide some practical tools: (1) a list of clinical features strongly suggestive of a distinctive CDG; (2) a table of clinical, biochemical and laboratory findings reported in CDG, arranged per organ/system; (3) an overview of the affected organs/systems in each CDG; and (4) a diagnostic decision tree in face of a patient with a suspicion of CDG. Most important is to keep in mind a CDG in any unexplained syndrome, in particular when there is neurological involvement. This mini-review enumerates clinical and biochemical hallmarks of these diseases and the biochemical and genetic testing available, and provides an updated list and information on identified CDG. The main aim is to act as a CDG diagnosis simplified guide for healthcare professionals and, additionally, as an awareness and lobbying tool to help in the effectiveness and promptness of CDG diagnosis.
KW - CDG
KW - Diagnosis
KW - MS
KW - Molecular testing
KW - NGS
KW - Whole Exome Sequencing
UR - http://www.scopus.com/inward/record.url?scp=85056729645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056729645&partnerID=8YFLogxK
U2 - 10.1016/j.ymgme.2018.11.003
DO - 10.1016/j.ymgme.2018.11.003
M3 - Comment/debate
C2 - 30454869
AN - SCOPUS:85056729645
SN - 1096-7192
VL - 126
SP - 1
EP - 5
JO - Biochemical Medicine and Metabolic Biology
JF - Biochemical Medicine and Metabolic Biology
IS - 1
ER -